ATE349511T1 - Mikroorganismen für die behandlung oder vorbeugung von fettleibigkeit und diabetes mellitus und pharmazeutische zusammensetzungen, die diese enthalten - Google Patents

Mikroorganismen für die behandlung oder vorbeugung von fettleibigkeit und diabetes mellitus und pharmazeutische zusammensetzungen, die diese enthalten

Info

Publication number
ATE349511T1
ATE349511T1 AT01908427T AT01908427T ATE349511T1 AT E349511 T1 ATE349511 T1 AT E349511T1 AT 01908427 T AT01908427 T AT 01908427T AT 01908427 T AT01908427 T AT 01908427T AT E349511 T1 ATE349511 T1 AT E349511T1
Authority
AT
Austria
Prior art keywords
microorganisms
obesity
prevention
treatment
diabetes mellitus
Prior art date
Application number
AT01908427T
Other languages
English (en)
Inventor
Chuckbook-Rhi
Hea-Jung Joung
Bong-Cheol Kim
Hang-Rae Kim
N Chuckbook-Rhi
Young-Bae Bang
Original Assignee
Bioneer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR10-2000-0049805A external-priority patent/KR100404236B1/ko
Application filed by Bioneer Corp filed Critical Bioneer Corp
Application granted granted Critical
Publication of ATE349511T1 publication Critical patent/ATE349511T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/02—Acetobacter
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/823—Acetobacter
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT01908427T 2000-05-17 2001-02-23 Mikroorganismen für die behandlung oder vorbeugung von fettleibigkeit und diabetes mellitus und pharmazeutische zusammensetzungen, die diese enthalten ATE349511T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20000026379 2000-05-17
KR10-2000-0049805A KR100404236B1 (ko) 2000-05-17 2000-08-26 비만 또는 당뇨병 치료용 미생물 및 상기 미생물을포함하는 의약 조성물

Publications (1)

Publication Number Publication Date
ATE349511T1 true ATE349511T1 (de) 2007-01-15

Family

ID=26637996

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01908427T ATE349511T1 (de) 2000-05-17 2001-02-23 Mikroorganismen für die behandlung oder vorbeugung von fettleibigkeit und diabetes mellitus und pharmazeutische zusammensetzungen, die diese enthalten

Country Status (8)

Country Link
US (4) US6808703B2 (de)
EP (1) EP1282687B1 (de)
JP (1) JP4580542B2 (de)
CN (1) CN1380902B (de)
AT (1) ATE349511T1 (de)
AU (1) AU3617001A (de)
DE (1) DE60125529T2 (de)
WO (1) WO2001088095A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002050311A2 (en) * 2000-12-21 2002-06-27 Societe Des Produits Nestle S.A. Lactobacillus strain producing levan and its use in human or pet food products
US6942857B2 (en) * 2002-08-09 2005-09-13 Bioneer Corporation Microorganisms for preventing and/or treating obesity or diabetes mellitus
DK1545562T3 (da) * 2002-09-09 2006-08-21 Tno Forgrenede alfa-glucaner til vægtregulering
WO2004076657A2 (en) 2003-02-28 2004-09-10 Mcgill University Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides
JP5401733B2 (ja) * 2005-02-11 2014-01-29 バイオラクティス インコーポレイティド プロバイオティクス及びシンバイオティックとしてのラクトバチルス・ケフィラノファシエンス（Ｌａｃｔｏｂａｃｉｌｌｕｓｋｅｆｉｒａｎｏｆａｃｉｅｎｓ）の使用
CN102225078B (zh) * 2005-07-26 2012-12-26 内斯特克有限公司 抗肥胖剂及抗肥胖食品
SE529185C2 (sv) 2005-10-07 2007-05-22 Arla Foods Amba Användning av probiotiska bakterier för tillverkning av livsmedel eller läkemedel för förhindrande av övervikt
WO2007084059A1 (en) * 2006-01-20 2007-07-26 Bjoerk Inger A food composition comprising amino acids
PL1981516T3 (pl) * 2006-01-27 2019-03-29 Dupont Nutrition Biosciences Aps Zastosowanie mikroorganizmów probiotycznych w leczeniu i zapobieganiu otyłości i pokrewnym zaburzeniom
US8309076B2 (en) * 2006-08-04 2012-11-13 Bioneer Corporation Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation
JP5089942B2 (ja) * 2006-09-04 2012-12-05 雪印メグミルク株式会社 内臓脂肪蓄積抑制剤
AU2007292786B2 (en) * 2006-09-04 2013-02-14 Megmilk Snow Brand Co., Ltd. Agent for accelerating the increase in and/or preventing the decrease in blood adiponectin level, and visceral fat accumulation inhibitor
EP2073643A2 (de) * 2006-10-18 2009-07-01 DSMIP Assets B.V. Verkapselung von hitze- und feuchtigkeitsempfindlichen substanzen
EP1987726A1 (de) * 2007-05-01 2008-11-05 Friesland Brands B.V. Wohlschmeckendes Nahrungsmittel mit Neutralisierungsmittel für Verbindungen mit Nebenwirkungen
EP2011506A1 (de) 2007-07-05 2009-01-07 Nestec S.A. Ergänzung zu einer Schwangerschaftsdiät
JP2009114163A (ja) * 2007-11-05 2009-05-28 Nippon Energy Kenkyusho:Kk 複合微生物の培養生成物を有効成分とする血糖降下剤および血糖降下機能食品
JP5554994B2 (ja) * 2007-11-19 2014-07-23 株式会社カネカ 乳酸菌含有製剤
EP2065048A1 (de) * 2007-11-30 2009-06-03 Institut Pasteur Verwendung eines L.-casei-Stammes zur Herstellung einer Zusammensetzung zur Mastzellenaktivierung
KR101746227B1 (ko) * 2008-03-07 2017-06-12 유키지루시 메그밀크 가부시키가이샤 아디포넥틴의 분비 촉진 및/또는 감소 억제용 제제
PT2100604E (pt) 2008-03-10 2012-07-24 Nestec Sa Ácidos dicarboxílicos de cadeia média e os seus derivados e doenças metabólicas
US20110189149A1 (en) * 2008-06-20 2011-08-04 Remy Burcelin New Uses of Lactic Acid Bacteria and Bifidobacteria
WO2010096550A2 (en) 2009-02-18 2010-08-26 University Of Florida Research Foundation, Inc. Lactobacillus supplement for alleviating type 1 diabetes
JP5569710B2 (ja) * 2009-02-27 2014-08-13 国立大学法人広島大学 肥満予防又は改善剤
KR101292714B1 (ko) * 2009-03-10 2013-08-05 주식회사 지니스 미생물을 이용한 비만 및 비만으로 야기된 대사성 질환의 예방과 치료
CN104784220A (zh) * 2009-06-19 2015-07-22 杜邦营养生物科学有限公司 治疗糖尿病及相关病症的双歧杆菌
CN101703528B (zh) * 2009-11-25 2012-07-04 王立平 一种治疗糖尿病的复合微生物制剂及其制备方法和应用
CN102935092B (zh) * 2010-06-09 2014-03-26 景岳生物科技股份有限公司 新颖乳杆菌及其组合物和在制备改善糖尿病及其并发症药物中的应用
ES2389547B1 (es) * 2010-12-07 2013-08-08 Consejo Superior De Investigaciones Científicas (Csic) Bifidobacterium cect 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas.
KR101234582B1 (ko) * 2011-04-22 2013-02-19 전남대학교산학협력단 알파 글루코시다제 활성 저해용 조성물
KR101228035B1 (ko) * 2011-06-29 2013-01-30 주식회사 쎌바이오텍 신규한 유산균 및 이를 포함하는 당뇨병 예방 및 치료용 조성물
CN102533588B (zh) * 2011-12-06 2013-12-11 光明乳业股份有限公司 一株产胞外多糖的短乳杆菌及其应用
EP2836224A4 (de) 2012-02-29 2015-12-16 Ethicon Endo Surgery Inc Zusammensetzungen von biozönose und zugehörige verfahren
JP5967527B2 (ja) * 2012-06-22 2016-08-10 国立研究開発法人産業技術総合研究所 食欲増進かつ体重増加抑制剤
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
CA2885537C (en) * 2012-09-20 2021-11-23 Prothera, Inc. Probiotic compositions and methods for the treatment of obesity and obesity-related conditions
WO2014171478A1 (ja) 2013-04-17 2014-10-23 サントリーホールディングス株式会社 ラクトバチルス属菌含有組成物
CN103275905B (zh) * 2013-05-31 2014-12-10 江南大学 具有预防糖尿病作用的鼠李糖乳杆菌ccfm0528
JP6637885B2 (ja) 2013-07-21 2020-01-29 ペンデュラム セラピューティクス， インコーポレイテッド マイクロバイオームの特性解明、モニタリング、および処置のための方法およびシステム
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
AU2015339576B2 (en) 2014-10-27 2020-02-06 Glytec, Llc Subcutaneous outpatient management
CA2964480A1 (en) 2014-10-31 2016-05-06 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
WO2016149687A1 (en) * 2015-03-18 2016-09-22 Whole Biome, Inc. Methods and compositions relating to microbial treatment and diagnosis of skin disorders
US20160353774A1 (en) * 2015-06-02 2016-12-08 Mead Johnson Nutrition Company Nutritional compositions comprising spore-forming probiotics
WO2017031440A1 (en) 2015-08-20 2017-02-23 Aseko, Inc. Diabetes management therapy advisor
CN107028985A (zh) * 2016-02-04 2017-08-11 深圳华大基因研究院 厚壁菌类益生菌在预防和/或治疗糖尿病及其相关疾病中的应用
JP6785509B2 (ja) * 2016-02-24 2020-11-18 Ｎｏｓｔｅｒ株式会社 ロイコノストック メセンテロイデスが産生する菌体外多糖を有効成分として含む代謝異常の予防または治療用組成物
US10653728B2 (en) 2016-10-17 2020-05-19 New York University Probiotic compositions for improving metabolism and immunity
MY197201A (en) 2017-02-10 2023-05-31 Perfect China Co Ltd Novel probiotics bifidobacteria strains
EP3662087B1 (de) * 2017-08-06 2022-10-05 Second Genome, Inc. Streptococcus australis als ein biotherapeutikum
JP2020532515A (ja) 2017-08-30 2020-11-12 ペンデュラム セラピューティクス， インコーポレイテッド マイクロバイオーム関連障害の処置のための方法および組成物
EP3688196A4 (de) 2017-09-26 2021-07-14 Second Genome, Inc. Gemella sanguinis als biotherapeutika
TWI710321B (zh) * 2018-05-03 2020-11-21 綠茵生技股份有限公司 低糖蔬果酵素液之製作方法
JP7219026B2 (ja) * 2018-07-11 2023-02-07 雪印メグミルク株式会社 食後血糖値上昇抑制用組成物及びその製造方法
EP3823651A4 (de) 2018-07-19 2022-04-27 Pendulum Therapeutics, Inc. Verfahren und zusammensetzungen zur mikrobiellen transplantation
JP7267020B2 (ja) * 2019-01-24 2023-05-01 株式会社明治 血糖値上昇抑制作用を有する発酵乳
JP2022522151A (ja) * 2019-02-26 2022-04-14 インダストリー ファウンデーション オブ チョンナム ナショナル ユニバーシティー 新規なラクトバチルスサケイｃｖｌ－００１菌株又はその培養液を含む骨疾患又は代謝性疾患改善、予防又は治療用組成物
CN110184214B (zh) * 2019-05-21 2022-07-01 黑龙江大学 一种开菲尔乳杆菌及其菌制剂
CN110144311B (zh) * 2019-05-21 2022-07-01 黑龙江大学 一种开菲尔乳杆菌及其菌制剂
CN111587952A (zh) * 2020-05-27 2020-08-28 佛山科学技术学院 一种降低家犬体脂沉积的益生菌添加剂
CN111661933B (zh) * 2020-06-30 2022-08-16 武汉合缘绿色生物股份有限公司 一种用于调节水体营养及预防病害的生物制剂及其制备方法
CN113512520B (zh) * 2021-04-29 2022-04-26 右江民族医学院 富铬富锌醋酸杆菌及其制备方法和应用
EP4183403A1 (de) * 2021-11-19 2023-05-24 Lietuvos Sveikatos Mokslu Universitetas Modifikation von fäkalen mikrobiota mit kapseln, die gram-positive bakterien enthalten
CN116121154B (zh) * 2023-04-10 2023-06-27 四川厌氧生物科技有限责任公司 一种乳明串珠菌及其应用
CN117925484B (zh) * 2024-03-19 2024-07-09 山东中科嘉亿生物工程有限公司 一株改善睡眠呼吸暂停的罗伊氏粘液乳杆菌jylb-101及其产品和应用
CN118374560B (zh) * 2024-06-26 2024-09-20 天津科技大学 一种发酵粘液乳杆菌胞外多糖及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0075604A1 (de) * 1981-09-24 1983-04-06 Asahi Kasei Kogyo Kabushiki Kaisha Mittel zur Senkung des Blutzuckerspiegels
US4568557A (en) * 1983-05-11 1986-02-04 Warner-Lambert Company Process for producing snack food product with high dietary fiber content
JPS615019A (ja) * 1984-06-18 1986-01-10 Nakano Vinegar Co Ltd 血糖低下剤
AU596961B2 (en) * 1985-03-08 1990-05-24 Takeda Chemical Industries Ltd. Saccharide digestion inhibiting composition
US5527772A (en) * 1987-10-20 1996-06-18 Holick; Michael F. Regulation of cell proliferation and differentiation using peptides
JP2928335B2 (ja) * 1989-06-26 1999-08-03 株式会社ヤクルト本社 抗高血圧剤および飲食品
JP2939491B2 (ja) * 1989-12-11 1999-08-25 株式会社アドバンス 機能性食品
JPH0735339B2 (ja) * 1991-09-09 1995-04-19 雪印乳業株式会社 血清コレステロール上昇抑制剤及び飲食品
JP3202053B2 (ja) * 1992-01-09 2001-08-27 カネボウ株式会社 腸溶性造粒物
JP3187502B2 (ja) * 1992-01-09 2001-07-11 カネボウ株式会社 腸溶性造粒物
CA2127392C (en) * 1993-07-08 2008-05-27 Hideki Sunohara Process for producing capsule and capsule obtained thereby
CN1105883A (zh) * 1994-01-31 1995-08-02 财团法人京都巴斯德研究所 用于增强免疫功能的乳杆菌
JPH107577A (ja) * 1996-06-17 1998-01-13 Yakult Honsha Co Ltd 血糖降下剤
EP1067945B1 (de) * 1998-04-01 2006-01-04 Ganeden Biotech, Inc. Erfahren zür verringerung von cholesterin mit bacillus coagulans sporen, systeme un zusammensetzungen
EP0956867A1 (de) * 1998-05-12 1999-11-17 Franz-Peter Dr. Liebel Verwendung von Flavonoidglykosiden, Gerbstoffen und Mikroorganismen zur Therapie und Prophylaxe des Diabetes mellitus
US6042823A (en) * 1998-07-02 2000-03-28 Amano Pharmaceuticals Co., Ltd. Enzyme composition and use thereof
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US6080401A (en) * 1998-11-19 2000-06-27 Reddy; Malireddy S. Herbal and pharmaceutical drugs enhanced with probiotics
US6641808B1 (en) * 1999-09-22 2003-11-04 Lacpro Industries, Llc Composition for treatment of obesity
US6464607B1 (en) * 1999-12-15 2002-10-15 The Goodyear Tire & Rubber Company Power transmission belt
US6486314B1 (en) * 2000-05-25 2002-11-26 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Glucan incorporating 4-, 6-, and 4, 6- linked anhydroglucose units
US6942857B2 (en) * 2002-08-09 2005-09-13 Bioneer Corporation Microorganisms for preventing and/or treating obesity or diabetes mellitus

Also Published As

Publication number Publication date
CN1380902A (zh) 2002-11-20
EP1282687B1 (de) 2006-12-27
US20050112112A1 (en) 2005-05-26
CN1380902B (zh) 2010-10-27
AU3617001A (en) 2001-11-26
DE60125529T2 (de) 2007-10-04
EP1282687A1 (de) 2003-02-12
US20030180273A1 (en) 2003-09-25
US6808703B2 (en) 2004-10-26
WO2001088095A1 (en) 2001-11-22
JP2001321163A (ja) 2001-11-20
JP4580542B2 (ja) 2010-11-17
US20030180271A1 (en) 2003-09-25
DE60125529D1 (de) 2007-02-08
US20020037577A1 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
ATE349511T1 (de) Mikroorganismen für die behandlung oder vorbeugung von fettleibigkeit und diabetes mellitus und pharmazeutische zusammensetzungen, die diese enthalten
TN2011000415A1 (en) Pharmaceutical composition comprising a sglt2 inhibitor a dpp-i v inhibitor and optionally a further antidiabetic agent and uses thereof
ATE431816T1 (de) Carbonsaeuren und ihre derivate und pharmazeutische zusammensetzungen die diese enthalten
IL151473A0 (en) O-aryl glucoside derivatives and pharmaceutical compositons containing the same
BR0112685A (pt) Composição nutricional
MX2010001560A (es) Composicion farmaceutica que comprende un inhibidor de sglt2 en combinacion con un inhibidor de dpp-iv.
SG170119A1 (en) Nutritional composition comprising indigestible oligosaccharides
UY26391A1 (es) Inhibidores sglt2 de glucosidos de c-arilo y metodo
BR0114310A (pt) Derivados do glicopiranosiloxibenzilbenzeno e composições medicinais contendo os mesmos
UA100008C2 (ru) Комбинированное лечение ингибиторами sglt-2 (натрийзависимый сопереносчик глюкозы 2) и фармацевтической композицией, которая их содержит
WO2006032500A3 (en) Immunogenic composition
TW200733968A (en) Stabilized lanthanum carbonate compositions
BR0107901A (pt) Composto, composição farmacêutica, método para o trtamento de enfermidade, para o trtamento e/ou prevenção de condições mediadas por receptores nucleares, e para o tratamento e/ou prevenção de diabetes e/ou obesidade, uso de um composto, e, método para tratar diabetes de tipo i, diabetes de tipo ii, tolerância à gligose prejudicada, resistência à insulina ou obesidade
TW200509947A (en) Composition containing β-glucan and constipation improver, immune activator and moisturizer for dermatic usage using such composition
ATE190840T1 (de) Zusammensetzung zur behandlung der parkinson- krankheit
BR0314335A (pt) Composto, uso do mesmo, composição farmacêutica, e métodos para o tratamento e/ou prevenção de condições mediadas por receptores nucleares, e de diabetes de tipo i, diabetes de tipo ii, tolerância prejudicada à glicose, resistência à insulina ou obesidade
SI1455802T1 (sl) Uporaba hitozanskih oligosaharidov
BRPI0517701A (pt) uso de um composto na preparação de medicamentos para o tratamento de diabetes mellitus
PT1254146E (pt) Processos de preparacao de polimeros de claritromicina e novo polimorfo iv
KR920701249A (ko) 글리코실화 인슐린
BR0112919A (pt) Uso de óleos essenciais para combater infecção do trato gi por organismos semelhantes a helicobacter
WO2025024305A3 (en) Irak4 degraders and uses thereof
CA2412789A1 (en) Compositions for improving mental concentration
GB2456475A (en) Composition for the treatment of skin conditions
WO2006023342A3 (en) Synergistic conjugated linoleic acid (cla) and carnitine combination

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties